• Corpus ID: 13593014

Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation.

@article{Poli2003SafetyAE,
  title={Safety and effectiveness of low dose oral vitamin K1 administration in asymptomatic out-patients on warfarin or acenocoumarol with excessive anticoagulation.},
  author={Daniela Poli and Emilia Antonucci and A. Lombardi and Gian Franco Gensini and Rosanna Abbate and Domenico Prisco},
  journal={Haematologica},
  year={2003},
  volume={88 2},
  pages={
          237-8
        }
}
The management of asymptomatic overanticoagulation with low dose vitamin K1 is recommended in patients taking oral anticoagulants, independently of the type of coumarin being administered. To evaluate the safety and effectiveness of this practice we observed 127 patients on warfarin and 14 on acenocoumarol, who received 2 mg oral vitamin K1 on at least one occasion. At the first measurement, international normalized ratio (INR) mean values were significantly lower in patients on acenocoumarol… 

Topics from this paper

Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review
TLDR
Evidence from randomized controlled trials supports the use of low-dose oral vitamin K therapy as a treatment that promptly reduces the INR, and suggests that this occurs infrequently when small doses are administered orally.
Management of excessive anticoagulant effect due to vitamin K antagonists.
TLDR
The evidence supporting various treatment modalities and suggestions for treatment are reviewed and future advances in this area will likely focus on evaluations of the relative merits of FFP and PCCs.
Patients who take uneven doses of acenocoumarol exhibit significant fluctuating levels of anticoagulation
TLDR
A prospective study comparing a group of 40 patients taking uneven doses of acenocoumarol and another group of 10 patients with uniform doses to assess possible fluctuations of anticoagulation found consistent association was found between every INR value and the dose administered to the patient 2 days before.
Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient
TLDR
Treating patients with supra-therapeutic INR in the presence of major bleeding, treatment with intravenous vitamin K and prothrombin complex concentrate is the most effective therapy.
Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review.
TLDR
Low dose oral vitamin K appears as the preferable strategy for rapidly restoring therapeutic INR levels in asymptomatic patients who present with an excessively prolonged INR due to warfarin therapy.
Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.
TLDR
Limited evidence suggests that oral and intravenous vitamin K are equivalent and more effective for excessive anticoagulation than simply withholding warfarin sodium.
Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.
TLDR
Limited evidence suggests that oral and intravenous vitamin K are equivalent and more effective for excessive anticoagulation than simply withholding warfarin sodium.
Urgent reversal of vitamin K antagonist therapy
TLDR
Therapeutic options for acute reversal of VKA therapy include: vitamin K, fresh frozen plasma (FFP), prothrombin complex concentrate (PCC) and perhaps activated recombinant factor VII.
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment
TLDR
Clinicians are still required to initiate and monitor vitamin K antagonists while mitigating the risks of bleeding and thrombosis, and recommen-dations designed to assist clinicians in estimating and managing bleeding risk in patients receiving oral vitamin Kantagonists are provided.
Treatment of coumarin‐associated coagulopathy: a systematic review and proposed treatment algorithms
TLDR
Vitamin K therapy is an effective treatment for INR prolongation in patients with coumarin‐associated coagulopathy; coagulation factor replacement is required, in addition, in Patients with major bleeding or with indication for immediate correction of their INR.
...
1
2
...